Seminars in Oncology
Volume 33, Supplement 11 , Pages 42-45, December 2006

Targeted Agents for Adjuvant Therapy of Colon Cancer

GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) and Hôpital Saint-Antoine, Paris, France

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr de Gramont has received honoraria from Roche, Genentech, and Sanofi-Aventis. Dr Tournigand has received honoraria from Roche and Sanofi-Aventis. Dr André has received honoraria from Roche, Merck, and Sanofi-Aventis. Dr Louvet has received honoraria from Roche, Aventis, Amgen, and Sanofi-Aventis.

PII: S0093-7754(06)00383-6

doi:10.1053/j.seminoncol.2006.10.006

Seminars in Oncology
Volume 33, Supplement 11 , Pages 42-45, December 2006

Article Tools

* Image Usage & Resolution